Table 4.

Transplantation Characteristics Associated with Tim-3 Cellular Expression^*

Clinical Variables	CD3+ T cells	CD4+ T cells	CD8+ T cells	CD19+ B cells	CD56+ NK cells
Age, patient†	.58	.90	.83	.60	P = .002
CMV serostatus,   patient‡	P = .01	P = .01	.30	P = .02	.83

^*Univariate associations of the percentage of Tim-3⁺ blood mononuclear cells in GVHD⁺ cases and GVHD⁻ case-controls studied during the first 100 days after allogeneic HCT (P values and direction of association). Study includes 22 HCT patients (14 acute GVHD⁺ cases and 8 GVHD⁻ case-controls) and 61 patient samples (32 cases and 29 case-controls). Samples from case and case-control patients were matched for time post transplantation: median 30 (range, 20 to 55) days and 32 (range, 25 to 36) days, respectively (P = .97). No significant effect was observed for sex, sex match, donor type (related, unrelated), HLA match, donor CMV serostatus, HSC source (blood, marrow), and TBI >1000 cGy.

^†Increasing patient age by decade.

^‡CMV serostatus (positive patient, negative donor) pretransplantation.